Title: Recommendations

Context:
We do not recommend for or against abuse deterrent formulations for LOT. Our searches identified two  RCTs in which the benefits of co-prescribing of naloxone with opioids were examined.[143,144] However, both RCTs were rated as low to very low quality with short-term follow-up. One open-label RCT enrolling  453 patients with chronic low back pain considered the safety and tolerability of an abuse deterrent formulation of oxycodone/naloxone relative to oxycodone or morphine at 12-week follow-up.[143]  Another RCT considered the safety and efficacy of oxycodone/naloxone prolonged-release relative to  oxycodone prolonged-release in 184 patients with moderate-to-severe chronic cancer pain at four-week  follow-up.[144] An observational study (not included in the evidence review) suggested that the  introduction of abuse deterrent opioid formulations did not help reduce abuse of opioids as a class and  that patients may switch from one opioid to another based on the availability or the lack of availability of  abuse deterrent formulations.[145]

Question: What is the stance regarding the abuse deterrent formulations for LOT?

Answer: do not recommend for or against